These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35580380)

  • 1. Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern.
    Pondé RAA
    Virology; 2022 Jul; 572():44-54. PubMed ID: 35580380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.
    Tsai MS; Shih WT; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2022 May; 149():112802. PubMed ID: 35279013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
    Wang R; Chen J; Gao K; Wei GW
    Genomics; 2021 Jul; 113(4):2158-2170. PubMed ID: 34004284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
    Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
    Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
    Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.
    Khan A; Zia T; Suleman M; Khan T; Ali SS; Abbasi AA; Mohammad A; Wei DQ
    J Cell Physiol; 2021 Oct; 236(10):7045-7057. PubMed ID: 33755190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
    Zhang L; Cui Z; Li Q; Wang B; Yu Y; Wu J; Nie J; Ding R; Wang H; Zhang Y; Liu S; Chen Z; He Y; Su X; Xu W; Huang W; Wang Y
    Commun Biol; 2021 Oct; 4(1):1196. PubMed ID: 34645933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor-binding domain mutations: Receptor affinity versus neutralization of receptor interaction.
    Vogel M; Augusto G; Chang X; Liu X; Speiser D; Mohsen MO; Bachmann MF
    Allergy; 2022 Jan; 77(1):143-149. PubMed ID: 34240429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor.
    Sinha S; Tam B; Wang SM
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift.
    Li T; Cui Z; Jia Y; Liang Z; Nie J; Zhang L; Wang M; Li Q; Wu J; Xu N; Liu S; Li X; An Y; Han P; Zhang M; Li Y; Qu X; Wang Q; Huang W; Wang Y
    J Med Virol; 2022 May; 94(5):2108-2125. PubMed ID: 35032057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor.
    Naresh GKRS; Guruprasad L
    J Biomol Struct Dyn; 2023 Apr; 41(6):2368-2381. PubMed ID: 35109768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease.
    Perez-Gomez R
    J Dev Biol; 2021 Dec; 9(4):. PubMed ID: 34940505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
    Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
    Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.